DGIdb - RB1 Gene Record

RB1 5925 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

5925
RB TRANSCRIPTIONAL COREPRESSOR 1
RB1
OSRC
PPP1R130
RB
p105-Rb
pRb
pp110
614041
9884
ENSG00000139687
OTTHUMG00000016900
4795
p110-RB1
Retinoblastoma-associated protein
P06400

Gene Info:

Gene Biotype	PROTEIN_CODING

(9 More Sources)

Gene Categories: Category Details

TRANSCRIPTION FACTOR COMPLEX
TUMOR SUPPRESSOR
KINASE
DRUG RESISTANCE
DRUGGABLE GENOME
CLINICALLY ACTIONABLE
TRANSCRIPTION FACTOR

Publications:

Bisi et al., 2016, Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression., Mol. Cancer Ther.
Dalgard et al., 2008, Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma., Clin. Cancer Res.
Rushlow et al., 2013, Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies., Lancet Oncol.
Ou et al., 2017, Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?, Lung Cancer
Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.
Vora et al., 2014, CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors., Cancer Cell
Herrera-Abreu et al., 2016, Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer., Cancer Res.
Zhang et al., 2012, A novel retinoblastoma therapy from genomic and epigenetic analyses., Nature
Hassan et al., 2014, Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors., Oncotarget
Jorda R et al., 2011, Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity., J Med Chem
Livi et al., 2013, Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors., Aging (Albany NY)
Windle et al., 1990, Retinoblastoma in transgenic mice., Nature
Piña et al., 2011, Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors., Clin Ophthalmol
Hanaford et al., 2016, DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets., Clin. Cancer Res.
Schröder et al., 2015, CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?, Front Oncol
Teh et al., 2016, An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma., Cancer Res.
Cen et al., 2012, p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells., Neuro-oncology
Michaud et al., 2010, Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts., Cancer Res.
Dean et al., 2010, Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure., Oncogene
Condorelli R et al., 2018, Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer., Ann Oncol
Infante et al., 2016, A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas., Clin. Cancer Res.
Dickson, 2014, Molecular pathways: CDK4 inhibitors for cancer therapy., Clin. Cancer Res.

FOSTAMATINIB RB1

Interaction Score: 2.81

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type retinoblastoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
22237022

Sources:
JAX-CKB
TRILACICLIB RB1

Interaction Score: 1.87

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung small cell carcinoma

Response Type resistant

Approval Status Preclinical - Cell line xenograft

PMIDs:
26826116

Sources:
JAX-CKB
RIBOCICLIB RB1

Interaction Score: 1.05

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type resistant

Approval Status Preclinical - Cell culture

PMIDs:
27542767 24795392 28151717 29236940

Sources:
JAX-CKB CIViC
LORLATINIB RB1

Interaction Score: 0.94

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung small cell carcinoma

Response Type predicted – resistant

Approval Status Clinical Study

PMIDs:
28285684

Sources:
JAX-CKB
PALBOCICLIB RB1

Interaction Score: 0.61

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type resistant

Approval Status Preclinical - Cell line xenograft

PMIDs:
27012813 26649278 27020857 27488531 22711607 20354191 20473330 29236940

Sources:
JAX-CKB CIViC
SELICICLIB RB1

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21417417

Sources:
DTC
ENTINOSTAT RB1

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type retinoblastoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
18483379 23498719

Sources:
JAX-CKB
TOPOTECAN RB1

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
26826116

Sources:
JAX-CKB
ASPARAGINASE RB1

Interaction Score: 0.37

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type decreased response

PMIDs:
28151717

Sources:
JAX-CKB
SAPANISERTIB RB1

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type skin cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
25261369

Sources:
JAX-CKB
PREDNISOLONE RB1

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Prednisolone

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type sensitive

PMIDs:
28151717

Sources:
JAX-CKB
SIROLIMUS RB1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type retinoblastoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
23454836 1689463 21468343

Sources:
JAX-CKB
PICTILISIB RB1

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Palbociclib + GDC-0941

Indication/Tumor Type triple-receptor negative breast cancer

Response Type no benefit

PMIDs:
27020857

Sources:
JAX-CKB
VORINOSTAT RB1

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type retinoblastoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
18483379 23498719

Sources:
JAX-CKB
ALPELISIB RB1

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25002028

Sources:
CIViC
MERCAPTOPURINE RB1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Mercaptopurine

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type decreased response

PMIDs:
28151717

Sources:
JAX-CKB
EVEROLIMUS RB1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Everolimus

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type sensitive

PMIDs:
28151717

Sources:
JAX-CKB
TRAMETINIB RB1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type decreased response

PMIDs:
27488531

Sources:
JAX-CKB
LARGAZOLE RB1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DEXAMETHASONE RB1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Dexamethasone

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type sensitive

PMIDs:
28151717

Sources:
JAX-CKB
BORTEZOMIB RB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Bortezomib

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type sensitive

PMIDs:
28151717

Sources:
JAX-CKB
METHOTREXATE RB1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Methotrexate

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type decreased response

PMIDs:
28151717

Sources:
JAX-CKB

Ensembl: ENSG00000139687
- Version: 101_38
Alternate Names:

RB1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

JAX-CKB: RB1

Version: 27-September-2017

Alternate Names:

5925 CKB Entrez Id

RB1 CKB Gene Synonym

OSRC CKB Gene Synonym

Gene Info:

Publications:

Bisi et al., 2016, Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression., Mol. Cancer Ther.

Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.

Teh et al., 2016, An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma., Cancer Res.

CIViC: RB1

Version: 14-September-2020

Alternate Names:

5925 Entrez Gene ID

4795 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Condorelli R et al., 2018, Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer., Ann Oncol

Dean et al., 2010, Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure., Oncogene

Michaud et al., 2010, Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts., Cancer Res.

NCI: RB1
- Version: 14-September-2017
Alternate Names:

Gene Info:

Publications:

Yen et al., 1994, Enhanced cell differentiation when RB is hypophosphorylated and down-regulated by radicicol, a SRC-kinase inhibitor., Exp. Cell Res.
DTC: RB1
- Version: 02-September-2020
Alternate Names:

Gene Info:

Publications:

Jorda R et al., 2011, Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity., J Med Chem
HingoraniCasas: ENSG00000139687
- Version: 31-May-2017
Alternate Names:

ENSG00000139687 Gene Symbol

RB1 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
Tempus: RB1
- Version: 11-November-2018
Alternate Names:

RB1 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Pharos: RB1
- Version: 01-February-2022
Alternate Names:

Retinoblastoma-associated protein Gene Name

P06400 UniProt ID

Gene Info:

Gene Categories:

KINASE, TRANSCRIPTION FACTOR

Publications:
MskImpact: RB1
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
GO: RB1
- Version: 01-February-2022
Alternate Names:

Gene Info:

Gene Categories:

TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR

Publications:
FoundationOneGenes: RB1
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: RB1
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: RB1
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Indication/Tumor Type	retinoblastoma
Response Type	sensitive
Approval Status	Preclinical

Indication/Tumor Type	lung small cell carcinoma
Response Type	resistant
Approval Status	Preclinical - Cell line xenograft

Indication/Tumor Type	T-cell adult acute lymphocytic leukemia
Response Type	resistant
Approval Status	Preclinical - Cell culture

Indication/Tumor Type	glioblastoma multiforme
Response Type	resistant
Approval Status	Preclinical - Cell line xenograft

Evidence Type	Actionable
Approval Status	Preclinical - Cell line xenograft
Response Type	sensitive

Indication/Tumor Type	skin cancer
Response Type	sensitive
Approval Status	Preclinical

combination therapy	Ribociclib + Prednisolone
Indication/Tumor Type	T-cell adult acute lymphocytic leukemia
Response Type	sensitive

combination therapy	Palbociclib + GDC-0941
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	no benefit

combination therapy	Ribociclib + Mercaptopurine
Indication/Tumor Type	T-cell adult acute lymphocytic leukemia
Response Type	decreased response

combination therapy	Ribociclib + Everolimus
Indication/Tumor Type	T-cell adult acute lymphocytic leukemia
Response Type	sensitive

combination therapy	Ribociclib + Dexamethasone
Indication/Tumor Type	T-cell adult acute lymphocytic leukemia
Response Type	sensitive

combination therapy	Ribociclib + Bortezomib
Indication/Tumor Type	T-cell adult acute lymphocytic leukemia
Response Type	sensitive

combination therapy	Ribociclib + Methotrexate
Indication/Tumor Type	T-cell adult acute lymphocytic leukemia
Response Type	decreased response

RB1 Gene Record

RB1 5925 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type retinoblastoma Response Type sensitive Approval Status Preclinical

PMIDs: 22237022

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type lung small cell carcinoma Response Type resistant Approval Status Preclinical - Cell line xenograft

PMIDs: 26826116

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type T-cell adult acute lymphocytic leukemia Response Type resistant Approval Status Preclinical - Cell culture

PMIDs: 27542767 24795392 28151717 29236940

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type lung small cell carcinoma Response Type predicted – resistant Approval Status Clinical Study

PMIDs: 28285684

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type glioblastoma multiforme Response Type resistant Approval Status Preclinical - Cell line xenograft

PMIDs: 27012813 26649278 27020857 27488531 22711607 20354191 20473330 29236940

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21417417

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type retinoblastoma Response Type sensitive Approval Status Preclinical - Cell line xenograft

PMIDs: 18483379 23498719

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell line xenograft Response Type sensitive

PMIDs: 26826116

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell culture Response Type decreased response

PMIDs: 28151717

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type skin cancer Response Type sensitive Approval Status Preclinical

PMIDs: 25261369

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Ribociclib + Prednisolone Indication/Tumor Type T-cell adult acute lymphocytic leukemia Response Type sensitive

PMIDs: 28151717

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type retinoblastoma Response Type sensitive Approval Status Preclinical

PMIDs: 23454836 1689463 21468343

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Palbociclib + GDC-0941 Indication/Tumor Type triple-receptor negative breast cancer Response Type no benefit

PMIDs: 27020857

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type retinoblastoma Response Type sensitive Approval Status Preclinical - Cell culture

PMIDs: 18483379 23498719

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25002028

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Ribociclib + Mercaptopurine Indication/Tumor Type T-cell adult acute lymphocytic leukemia Response Type decreased response

PMIDs: 28151717

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Ribociclib + Everolimus Indication/Tumor Type T-cell adult acute lymphocytic leukemia Response Type sensitive

PMIDs: 28151717

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell culture Response Type decreased response

PMIDs: 27488531

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type retinoblastoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
22237022

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung small cell carcinoma

Response Type resistant

Approval Status Preclinical - Cell line xenograft

PMIDs:
26826116

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type resistant

Approval Status Preclinical - Cell culture

PMIDs:
27542767 24795392 28151717 29236940

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung small cell carcinoma

Response Type predicted – resistant

Approval Status Clinical Study

PMIDs:
28285684

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type glioblastoma multiforme

Response Type resistant

Approval Status Preclinical - Cell line xenograft

PMIDs:
27012813 26649278 27020857 27488531 22711607 20354191 20473330 29236940

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

PMIDs:
21417417

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type retinoblastoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
18483379 23498719

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell line xenograft

Response Type sensitive

PMIDs:
26826116

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type decreased response

PMIDs:
28151717

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type skin cancer

Response Type sensitive

Approval Status Preclinical

PMIDs:
25261369

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Prednisolone

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type sensitive

PMIDs:
28151717

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type retinoblastoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
23454836 1689463 21468343

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Palbociclib + GDC-0941

Indication/Tumor Type triple-receptor negative breast cancer

Response Type no benefit

PMIDs:
27020857

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type retinoblastoma

Response Type sensitive

Approval Status Preclinical - Cell culture

PMIDs:
18483379 23498719

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
25002028

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Mercaptopurine

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type decreased response

PMIDs:
28151717

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Everolimus

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type sensitive

PMIDs:
28151717

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type decreased response

PMIDs:
27488531

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Dexamethasone

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type sensitive

PMIDs:
28151717

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Ribociclib + Bortezomib

Indication/Tumor Type T-cell adult acute lymphocytic leukemia

Response Type sensitive

PMIDs:
28151717